We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Slowdown in DNA Replication Leads to Cancer-Forming Genomic Damage

By LabMedica International staff writers
Posted on 19 Jul 2011
In a recent publication, cancer researchers described a mechanism for the formation of breakage in DNA at specific “fragile sites” that induced chromosomal instability, which is characteristic of cells in the early stages of cancer development.

Investigators at the Hebrew University of Jerusalem (Israel) employed sophisticated new methodology that allowed the study of single DNA molecules to study the basis for the formation of breaks at specific fragile sites. More...


They reported in the July 8, 2011, issue of the journal Molecular Cell that even under normal growth conditions, replication fork progression along the fragile chromosome site, FRA16C, was slow, and forks frequently stalled at adenine-thymine (A-T) rich sequences, leading to activation of additional origins to enable replication completion. Under mild replication stress, the frequency of stalling at A-T-rich sequences was further increased. Unlike in the entire genome, in the FRA16C region additional origins were not activated, suggesting that all potential origins were already activated under normal conditions.

The basis for FRA16C fragility was replication fork stalling at A-T-rich sequences and the inability of the cell to activate additional origins under replication stress. These results provide a mechanism explaining the replication stress sensitivity of fragile sites and thus, the basis for genomic instability during early stages of cancer development.

“A hallmark of most human cancers is accumulation of damage in the DNA, which drives cancer development,” said senior author Dr. Batsheva Kerem, professor of genetics at the Hebrew University of Jerusalem. “In the early stages of cancer development, the cells are forced to proliferate. In each cycle of proliferation, the DNA is replicated to ensure that the daughter cells have a full DNA. However, in these early stages the conditions for DNA replication are perturbed, leading to DNA breaks, which occur specifically in regions defined as ‘fragile sites.’”

Related Links:

Hebrew University of Jerusalem



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
POC Immunoassay Analyzer
Procise DX
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.